California Pharmacist Winter 2026 - Flipbook - Page 34
Respiratory
Jascayd (nerandomilast)
Jascayd is an oral phosphodiesterase 4B inhibitor that
regulates in昀氀ammation and
昀椀brosis pathways. It is the 昀椀rst
newly approved drug for this
indication in the last decade.
Boehringer Ingelheim
10/7/2025
Obstetrics and Gynecology
Lynkuet (elinzanetant)
Lynkuet is an oral, hormone-free treatment approved
for moderate-to-severe
vasomotor symptoms (VMS)
associated with. It is a dual neurokinin‑1 (NK1) and neurokinin‑3
(NK3) receptor antagonist and
is the 昀椀rst and only NK1/NK3
receptor–targeting therapy
approved for VMS.
Bayer
10/24/2025
Neurology
Kygevvi (doxecitine and
doxribtimine)
Kygevvi is an oral combination
drug of doxecitine and doxribtimine, two pyrimidine nucleosides and approved for the
treatment of thymidine kinase
2 de昀椀ciency (TK2d). This is the
昀椀rst FDA-approved treatment of
TK2d; it is considered an orphan
drug.
UCB, Inc.
11/3/2025
Oncology
Komzifti (ziftomenib)
Komzifti is an oral menin
inhibitor approved for adults
with relapsed or refractory
acute myeloid leukemia with a
susceptible nucleophosmin 1
mutation who had an inadequate response to any other
treatments. It is the 昀椀rst menin
inhibitor with a once-daily oral
dosing schedule.
Kura Oncology
11/13/2025
Cardiology
Redemplo (plozasiran)
Redemplo is a self-administered, subcutaneous injectable
apolipoprotein C-III small interfering ribonucleic acid (siRNA)
approved for familial chylomicronemia syndrome. This is the
昀椀rst siRNA therapy for FCS.
Arrowhead Pharmaceuticals
11/18/2025
Oncology
Hyrnuo (sevabertinib)
Hyrnuo is an oral kinase inhibitor with accelerated approval
for treating adult patients with
locally advanced or metastatic
non-squamous non-small cell
lung cancer that are human epidermal growth factor receptor
2 (HER2) mutation positive and
who have received systemic
therapy. This is the second
FDA-approved HER2-targeted
kinase inhibitor for this indication.
Bayer Healthcare Pharmaceuticals
11/19/2025
Nephrology, Immunology
Voyxact (sibeprenlimab-szsi)
Voyxact is a 昀椀rst-in-class proliferation-inducing ligand (APRIL)
blocker monoclonal antibody
for IgA nephropathy.
The injectable agent is indicated to reduce proteinuria in
adults with primary immunoglobulin A nephropathy at risk
for disease progression.
Otsuka Pharmaceutical
11/25/2025
Cardiology
Lerochol (lerodalcibep-liga)
Lerochol is a long-acting PCSK9
fusion protein for lowering LDL
cholesterol. This third-generation PCSK9 inhibitor is a
once-monthly subcutaneous
injection indicated as an adjunct
to diet and exercise to reduce
LDL-C in adults with hypercholesterolemia, including
heterozygous familial hypercholesterolemia.
LIB Therapeutics
12/12/2025
32
vol. 73, no.1 | California Pharmacist
